Answers are grounded in this paper and cite their sources.
Background Previous exposure to advanced treatments for IBD is considered to reduce remission rates in further therapy lines and optimal treatment sequences remain to be established. Methods We performed a retrospective propensity score-weighted cohort study including a total of 219 patients (281 therapy lines) with ulcerative colitis (UC) to compare the efficacy of first-line vedolizumab with second-line vedolizumab after previous anti-TNF and vice versa. Results While second-line vedolizumab after first-line anti-TNF resulted in clearly lower rates of clinical and steroid-free remission after 52 weeks compared with first-line vedolizumab, no statistically significant reduction in clinical or steroid-free remission was detected for second-line anti-TNF after first-line vedolizumab compared with first-line anti-TNF. Conclusion Exposure to vedolizumab was not associated with a statistically significant reduction in the effectiveness of subsequent anti-TNF antibodies in second-line therapy of UC, whereas prior exposure to anti-TNF antibodies was associated with a statistically significant reduction in the effectiveness of subsequent vedolizumab. These findings support considering vedolizumab as a first-line treatment option, although direct comparisons of treatment sequences are needed to determine the optimal treatment strategy.
No takes yet. Share an insight, caveat, or question.
Assel et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: